Creating An Efficient Clinical Trial Build System via The Clinical Trials Rapid Activation Consortium (CTRAC)
通过临床试验快速激活联盟 (CTRAC) 创建高效的临床试验构建系统
基本信息
- 批准号:10227524
- 负责人:
- 金额:$ 30.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2023-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse eventAreaAutomationCancer BurdenCancer CenterCatchment AreaClinicalClinical TrialsClinical Trials NetworkClinical trial protocol documentCommunitiesComplexCustomDevelopmentDiseaseEducationElectronic Health RecordExpenditureFormulariesFutureGoalsIndividualInfrastructureInstitutionIntervention StudiesInvestigational TherapiesLaboratoriesLeadershipMalignant NeoplasmsManualsMedication ErrorsMentorshipMethodsMissionModificationPatient CarePatientsPharmaceutical PreparationsPoliciesPopulation ResearchProceduresProcessProtocols documentationProviderResearchResearch PersonnelResourcesSiteSpecific qualifier valueStandardizationStructureSystemTestingTimeUniversitiesVendorWisconsinWorkanticancer researcharmbasecancer carecare providerscostimaging biomarkerimprovedinnovationmemberneoplasm resourcenext generationnovelpopulation basedstandard of caresupport networktreatment planning
项目摘要
PROJECT SUMMARY
Standard-of-care electronic health records (EHR)-based treatment plans support efficiency and quality
through standardization. However, treatment-plan builds for clinical trials, irrespective of the number of
patients, must be built from the ground up for each new trial and at each added site. Additionally,
investigational treatment plans often require configurations for novel medications, numerous ancillary
procedures, and research finance requirements. The current paradigm is costly, complex, and
inefficient. Representatives of five cancer centers agreed to be part of the project’s Clinical Trials Rapid
Activation Consortium (CTRAC). The project’s goal is to develop processes across multiple NCI-supported
cancer centers that will facilitate the development of single builds of EHR clinical-trial treatment plans that
can be deployed at multiple institutions in support of NCI- sponsored network studies. Members will
investigate the question: can a small consortium of clinical trials sites develop methods to standardize
workflows, drug formularies, drug administration procedures, and laboratory requirements leading to the
creation of the components for a standardized, electronic, clinical trials build system? Specific aims are as
follows: 1) To identify the tasks currently performed by EHR investigational treatment plans (SOPs, policies,
and workflows) and to define differences among these SOPs at the individual member sites of the
consortium; 2) To standardize the processes within each task where possible and document differences that
would require modifications across sites; 3) To develop a master assessment of EHR treatment-plan
modules that could be reused to perform components of the same research protocol tasks at multiple sites
while maintaining compliance with the requirements of member organizations of the consortium; 4) To
organize a leadership structure for the consortium that will work with the NCI and an EHR provider to
oversee this initiative to assure that adequate progress is made toward the ultimate goal of creating a more
automated electronic clinical-trial build system that will facilitate the activation of clinical trials across all NCI-
supported networks; 5) To build standardized electronic clinical-trial build modules that could undergo future
pilot testing at each institution for a specified group of NCI-sponsored clinical trials; and 6) To facilitate
development of metrics for the new EHR processes that can demonstrate whether more consistent patient
care, reduced medication errors, and fewer adverse events result from a standardized approach to clinical-
trial build modules.
项目总结
基于医疗标准电子健康记录(EHR)的治疗计划支持效率和质量
通过标准化。然而,临床试验的治疗计划建立,无论有多少
对于每个新的试验和每个增加的地点,必须从头开始建立患者。另外,
研究治疗计划通常需要配置新的药物、许多辅助药物
程序和研究经费要求。当前的模式成本高昂、复杂,而且
效率低下。五个癌症中心的代表同意参加该项目的快速临床试验
激活联盟(CTRAC)。该项目的目标是开发跨多个NCI支持的流程
癌症中心将促进开发单一版本的EHR临床试验治疗计划,
可以部署在多个机构,以支持NCI赞助的网络研究。成员将
调查这个问题:一个临床试验站点的小联盟能否开发出标准化的方法
工作流程、药物处方、给药程序和实验室要求
创建标准化、电子化、临床试验构建系统的组件?具体目标是
1)确定目前由EHR研究治疗计划(SOP、政策、
和工作流程),并定义这些SOP之间在各个成员站点的差异
联盟;2)在可能的情况下标准化每项任务中的流程,并记录差异
将需要跨站点进行修改;3)制定EHR治疗计划的总体评估
可重复使用的模块,用于在多个站点执行相同研究协议任务的组件
同时保持遵守联合体成员组织的要求;4)
组织财团的领导结构,该财团将与NCI和EHR提供商合作,以
监督这一计划,以确保朝着创造更多
自动化电子临床试验构建系统,将促进激活所有NCI-
支持的网络;5)建立标准化的电子临床试验构建模块,可以在未来
在每个机构为NCI赞助的一组指定的临床试验进行试点测试;以及6)促进
为新的电子病历流程制定衡量标准,以证明更一致的患者
医疗护理、减少用药差错和不良事件的减少源于标准化的临床方法-
试用构建模块。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HOWARD H. BAILEY其他文献
HOWARD H. BAILEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HOWARD H. BAILEY', 18)}}的其他基金
Stress keratin 17 and CD4/8 ratio as prognostic markers in HIV-related anogenital squamous cell precancers and cancers (Biospecimens/Biocohort)
应激角蛋白 17 和 CD4/8 比率作为 HIV 相关肛门生殖器鳞状细胞癌前病变和癌症的预后标志物 (Biospecimens/Biocohort)
- 批准号:
10620051 - 财政年份:2022
- 资助金额:
$ 30.02万 - 项目类别:
Defining Tumor Microenvironment and Response to Immune Checkpoint Blockade in HIV-related Anogenital Squamous Cell Carcinomas (Immuno/microenvironment)
HIV 相关肛门生殖器鳞状细胞癌中肿瘤微环境的定义和对免疫检查点阻断的反应(免疫/微环境)
- 批准号:
10620043 - 财政年份:2022
- 资助金额:
$ 30.02万 - 项目类别:
The MW Cancer Prevention Clinical Trials Network
MW 癌症预防临床试验网络
- 批准号:
10252839 - 财政年份:2020
- 资助金额:
$ 30.02万 - 项目类别:
The MW Cancer Prevention Clinical Trials Network
MW 癌症预防临床试验网络
- 批准号:
10475114 - 财政年份:2020
- 资助金额:
$ 30.02万 - 项目类别:
The MW Cancer Prevention Clinical Trials Network
MW 癌症预防临床试验网络
- 批准号:
10004825 - 财政年份:2020
- 资助金额:
$ 30.02万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 30.02万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 30.02万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 30.02万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 30.02万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 30.02万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 30.02万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 30.02万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 30.02万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 30.02万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 30.02万 - 项目类别: